:

Research Programs > CancerCenterClinicalTrials
Cancer Center Clinical Trials

Official Title:CALGB 30607: Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Ce
Date Window: 5/27/2009 - 5/27/2014
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To test how well sunitib works at preventing lung cancer recurrence or progression when given as maintenance therapy after standard chemotherapy treatment for advanced non small cell lung cancer. 

ClinicalTrials.gov identifier

NCT00693992

Official Title:CALGB 50303: Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Date Window: 7/26/2005 - 7/26/2014
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To compare the effectiveness of two different chemotherapy regimens for treating diffuse large B cell lymphoma.

ClinicalTrials.gov identifier
NCT00118209

Official Title:ECOG 2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide Alone and in Combination with Epoetin Alfa in Subjects with Low- or Intermediate-1 Risk myelodysplastic syndrome (MDS) and Sympt
Date Window: 10/27/2009 - 10/27/2014
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To test how well lenalidomide works with or without epoetin alfa to treat anemia in patients with myelodysplastic syndrome.

ClinicalTrials.gov identifier
NCT00843882


Official Title:CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition In COX-2 Expressing Advanced Non-Small Cell Lung Cancer
Date Window: 6/8/2010 - 6/8/2015
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
ClinicalTrials.gov identifier
NCT01041781

Official Title:CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Date Window: 12/8/2010 - 12/8/2015
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To compare the effectiveness of 6 versus 12 courses of standard chemotherapy after surgery for stage III colon cancer; and to test how well celecoxib works at preventing colon cancer recurrence when added to chemotherapy.

 

ClinicalTrials.gov identifier
NCT01150045

 

 


Official Title:CALGB 80802: Phase III Randomized Study of Sorafenib plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
Date Window: 6/12/2012 - 6/12/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To test how well chemotherapy works to treat advanced liver cancer when added to standard sorafenib treatment.

ClinicalTrials.gov identifier
NCT01015833


Official Title:ECOG 2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos
Date Window: 11/26/2012 - 11/26/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To compare the effectiveness of clofarabine to standard induction chemotherapy, and to test the effectiveness of decitabine as maintenance therapy, in patients over age 60 with acute myelogenous leukemia.

ClinicalTrials.gov identifier
NCT01041703


Official Title:ECOG 1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
Date Window: 11/19/2012 - 11/19/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To test how well bevacizumab works to prevent lung cancer recurrence when added to standard chemotherapy after complete surgical resection of non small cell lung cancer.

ClinicalTrials.gov identifier
NCT00324805


Official Title:SWOG 1007 (RxPONDER trial): A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or
Date Window: 9/6/2012 - 9/6/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To compare the effectiveness of hormonal therapy with or without chemotherapy in patients with 1-3 positive lymph nodes and an Oncotype recurrence score of 25 or less.

 
ClinicalTrials.gov identifier
NCT01272037


Seeking Patients with Asymptomatic Smoldering Multiple Myeloma for Lenalidomide Test Trial
Official Title:ECOG 3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma
Date Window: 11/21/2012 - 11/21/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To test how well lenalidomide works to treat asymptomatic smoldering multiple

ClinicalTrials.gov identifier
NCT01169337


1 - 10 Next

Contact

Location
Building 17B
3rd Floor, Suite E

Phone
Main (301) 295-8239/8219

Hours of Operation
Monday thru Friday
0700 - 1630